Select a category
Instablog9ja
21 m
11
NIDCOM boss, Abike Dabiri-Erewa, has replied critics asking her to focus on those in Nigeria who are guilty of the same crime as Patience Amaka Sunnberger.
She said as long as she is the Chair @nidcom_gov and diaspora issues are reported to them, they will deal with it. As of now Nigerians in Canada have taken the matter up with the relevant authorities.
Investopedia
21 m
9
:max_bytes(150000):strip_icc()/GettyImages-2165823902-129bbded011f4b76aaf7f5bf98713e64.jpg)
Discount retailer Big Lots (BIG) is reportedly seeking investors to avoid filing for Chapter 11 bankruptcy protections after an extended decline in sales and several quarters of losses.
The company has received at least one loan of up to $200 million so far this year, with reporting Big Lots has been in talks with potential investors over the last month.
A regulatory filing earlier this month indicated four Big Lots executives recently received "retention bonuses" totaling over $5 million, which and reported may be an indication a bankruptcy filing could be coming, with bonuses paid to ensure key leadership doesn't leave during the process.
The retailer has reportedly been working with consulting firm AlixPartners over the last year to manage costs as sales declined
Big Lots did not immediately respond to a request for comment.
Big Lots shares were down over 22% in early trading Thursday at about 72 cents per share. They've lost more than 90% of their value since the start of the year.
Do you have a news tip for Investopedia reporters? Please email us at [email protected]Read more on Investopedia
Instablog9ja
1 h
10
A lady has discloses an ‘undiscovered skincare’ that’s affordable for Nigerians.
She said Air Conditioner (AC) is undiscovered skincare, as it makes the body cool and fresh.
Kohl's Cuts Costs To Address A Challenging Consumer Environment
Kohl’s (KSS) Shares Rose Wednesda...
Investopedia
1 h
13
:max_bytes(150000):strip_icc()/INV_Kohls_Store_GettyImages-1487130596-92a3628d0758420e844c707826224620.jpg)
Kohl’s (KSS) shares rose Wednesday as cost reduction helped the retailer beat profit forecasts despite a drop in sales.
Kohl’s reported second-quarter earnings per share (EPS) of 59 cents, 14 cents above the average estimate of analysts surveyed by Visible Alpha. Revenue fell 4.2% to $3.5 billion and comparable store sales slipped 5.1%. Both figures were below expectations. Selling, general, and administrative (SG&A) expenses also declined 4.2%, to $1.2 billion.
Kohl’s now sees full-year revenue down 6%, compared with an earlier prediction of a 4% fall. But it lifted its profit outlook for the year, to a range of $1.75 to $2.25 a share, up from a previous forecast of $1.25 to $1.85 per share.
Kohl's anticipates that full-year comparable store sales will fall 5% versus the previous expectation of a decrease of 3%.
Shares of Kohl's, which edged higher Wednesday, have lost nearly a third of their value this year.
Chief Executive Officer Tom Kingsbury said his company has taken “significant action to reposition Kohl’s for future growth.” However, he said the gains were muted in part because of “a continued challenging consumer environment and softness in our core business.”
Kingsbury added that during the quarter, shoppers “exhibited more discretion in their spending.” Even so, he said, the company’s “conviction in our strategy remains strong.”
Do you have a news tip for Investopedia reporters? Please email us at [email protected]Read more on Investopedia
Instablog9ja
2 hrs
11
Single Nigerian women have placed their hands on their chest as rapper Falz uploaded a picture of him on ‘father duties.
The singer has uploaded a picture of himself with his child to the amazement of his fans.
Here's Why A Handful Of Pharmaceutical Stocks Rose Wednesday
Shares Of Several Drugmakers And Bi...
Investopedia
2 hrs
14
:max_bytes(150000):strip_icc()/GettyImages-19805223281-bae720bc6952496091a40da32bf01617.jpg)
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
Various regulatory decisions and clinical trial results boosted the top-performing pharmaceutical stocks: Gilead Sciences (GILD), Bristol-Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX).
Shares of Gilead Sciences rose about 2%, extending a multiday string of gains that has followed the approval of Livdelzi, a treatment for inflammatory liver disease that received clearance from the Food and Drug Administration (FDA) on Aug. 14. Gilead has also drawn positive attention for its portfolio of HIV treatments.
Bristol-Myers Squibb (BMY) shares added close to 2% after competitor Neurocrine Biosciences (NBIX) released mixed results from a mid-stage clinical trial of its schizophrenia treatment. Although a low dose of Neurocrine's drug helped reduce the severity of schizophrenia symptoms, the study raised concerns about whether the benefits would carry over in larger trials. Bristol-Myers Squibb's schizophrenia treatment KarXT is set for an approval decision from the FDA in September.
Vertex Pharmaceuticals (VRTX) shares were up almost 2% after the company said the FDA approved its new drug application for suzetrigine, an oral treatment designed to alleviate moderate to severe pain. The drug has reportedly been granted a priority evaluation from the regulator, with a projected action date of Jan. 30.
While much of the market's attention has been focused on blockbuster weight-loss treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), overall stock market returns in the industry have been relatively subdued this year. The SPDR S&P Pharmaceuticals ETF (XPH) is up around 7% in 2024, compared with gains of roughly 17% for the S&P 500.
Do you have a news tip for Investopedia reporters? Please email us at [email protected]Read more on Investopedia
